Extrawell Pharmaceutical Holdings Limited

SEHK:858 Stock Report

Market Cap: HK$126.7m

Extrawell Pharmaceutical Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Yi Xie

Chief executive officer

HK$1.4m

Total compensation

CEO salary percentage94.9%
CEO tenure10.9yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure13.5yrs

Recent management updates

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01
Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04
We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15
Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20
Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

CEO Compensation Analysis

How has Yi Xie's remuneration changed compared to Extrawell Pharmaceutical Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024HK$1mHK$1m

-HK$163m

Dec 31 2023n/an/a

-HK$159m

Sep 30 2023n/an/a

-HK$154m

Jun 30 2023n/an/a

-HK$13m

Mar 31 2023HK$1mHK$1m

HK$129m

Dec 31 2022n/an/a

HK$109m

Sep 30 2022n/an/a

HK$88m

Jun 30 2022n/an/a

HK$109m

Mar 31 2022HK$1mHK$1m

HK$131m

Dec 31 2021n/an/a

HK$12m

Sep 30 2021n/an/a

-HK$107m

Jun 30 2021n/an/a

-HK$114m

Mar 31 2021HK$1mHK$1m

-HK$121m

Dec 31 2020n/an/a

HK$6m

Sep 30 2020n/an/a

HK$133m

Jun 30 2020n/an/a

HK$108m

Mar 31 2020HK$1mHK$1m

HK$83m

Dec 31 2019n/an/a

HK$73m

Sep 30 2019n/an/a

HK$63m

Jun 30 2019n/an/a

HK$63m

Mar 31 2019HK$1mHK$1m

HK$64m

Dec 31 2018n/an/a

HK$51m

Sep 30 2018n/an/a

HK$39m

Jun 30 2018n/an/a

HK$34m

Mar 31 2018HK$1mHK$1m

HK$30m

Compensation vs Market: Yi's total compensation ($USD178.11K) is about average for companies of similar size in the Hong Kong market ($USD233.50K).

Compensation vs Earnings: Yi's compensation has been consistent with company performance over the past year.

CEO

Yi Xie (61 yo)

10.9yrs

Tenure

HK$1,386,000

Compensation

Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...

Board Members

NamePositionTenureCompensationOwnership
Yi Xie
Executive Chairman & CEO10.9yrsHK$1.39mno data
Yi Lou
Executive Director16.1yrsHK$557.00kno data
Yong Cheng
Deputy CEO & Executive Director10.9yrsHK$713.00k6.14%
HK$ 7.8m
Yi Guo
Executive Director1.6yrsno datano data
Sau Kuen Wong
Company Secretary & Executive Director16.1yrsHK$940.00kno data
Yumin Mao
Honorary Chairman and Chief Scientific Advisorno datano data7.95%
HK$ 10.1m
Lin Hu Fang
Independent Non-Executive Director23.8yrsHK$70.00kno data
Song Jin
Independent Non-Executive Director20.2yrsHK$70.00kno data
Li Zeng
Independent Non-Executive Directorless than a yearno datano data

13.5yrs

Average Tenure

61yo

Average Age

Experienced Board: 858's board of directors are seasoned and experienced ( 13.5 years average tenure).